timi天美传孟若羽

　　李学松 timi天美传孟若羽泌尿外科主任医师，教授，博士生导师，博士后导师，科室主任

　　2015年度第一届郭应禄泌尿外科青年医师奖获得者，2019年世界华人泌尿外科学会新星奖，2019年第叁届国之名医优秀风范奖。

　　在中英文杂志发表了二百余篇论文，第一或通讯作者发表厂颁滨论文70余篇。参编或编译泌尿外科专业书籍15部，主译3部，主编3部。

　　专业方向为泌尿系肿瘤和输尿管疾病的开放及微创治疗，尤其擅长复杂疑难的肾脏、输尿管及膀胱修复重建及泌尿系肿瘤的腹腔镜和达芬奇机器人手术，创新改良多项手术技术，是中国上尿路修复领域年青一代的开拓者和领军人物。

　　工作经历

　　2004-09 ~ 2009-08 timi天美传孟若羽　主治医师

　　2009-08 ~ 2015-09 timi天美传孟若羽　副主任医师

　　2012-09 ~ 2018-08 timi天美传孟若羽　副教授

　　2015-09 ~ 至今 timi天美传孟若羽　 主任医师

　　2018-09 ~ 至今 timi天美传孟若羽　 科室副主任 教授

　　学会任职

　　中华医学会泌尿外科分会泌尿男科工程学组委员(颁鲍础)、尿路修复联盟秘书长、颁鲍础青年委员、颁鲍础青年委员会微创学组副组长，中国机器人医师分会泌尿外科学组委员，中国医师协会泌尿外科医师分会(颁鲍顿础)委员兼副总干事、颁鲍顿础修复重建学组副组长，颁鲍顿础-鲍罢鲍颁协作组秘书长，中国医师协会毕业后医学教育外科专业委员会副主任委员，北京医学会泌尿外科学分会青年委员会副主任委员、北京医学会泌尿外科分会尿路修复及重建学组副组长、数字泌尿外科学组副组长，北京癌症防治学会泌尿系肿瘤工作委员会主任委员，中国医促会泌尿生殖委员会委员、泌尿外科疾病国际共识咨询委员会委员、中国研究型医院泌尿外科青年委员会副主任委员、北京健康促进会泌尿外科专业委员会委员。

　　担任《Current Opine in Urology中文版》编辑部主任兼副主编、《泌尿外科杂志(电子版)》副主编，《机器人外科学杂志》常务编委，《现代泌尿外科杂志》、《Translational Andrology and Urology》编委，《中华泌尿外科杂志》通讯编委，《Andrology》、《Annals of Surgical Oncology 》《Oncotarget 》、《Urology》、《Canadian Journal of urology》、《Clinical Genitourinary Cancer》、《Chinese Journal of Cancer Research (CJCR)》、《Chinese medical Journal》、《Current Drug Metabolism》、《Pathology》、《BMC Urology》《Current Medicinal Chemistry》、《Aging》《Cancer Biomarkers》、《Biomedicine & Pharmacotherapy》、《Archives of Medical Research》、《Therapeutic Advances in Urology》等中英文杂志审稿专家。

医学博士，教授，博士生导师，博士后导师

中华医学会泌尿外科分会泌尿男科工程学组委员(颁鲍础)、尿路修复联盟秘书长、颁鲍础青年委员、颁鲍础青年委员会微创学组副组长，中国机器人医师分会泌尿外科学组委员，中国医师协会泌尿外科医师分会(颁鲍顿础)委员兼副总干事、颁鲍顿础修复重建学组副组长，颁鲍顿础-鲍罢鲍颁协作组秘书长，中国医师协会毕业后医学教育外科专业委员会副主任委员，北京医学会泌尿外科学分会青年委员会副主任委员、北京医学会泌尿外科分会尿路修复及重建学组副组长、数字泌尿外科学组副组长，北京癌症防治学会泌尿系肿瘤工作委员会主任委员，中国医促会泌尿生殖委员会委员、泌尿外科疾病国际共识咨询委员会委员、中国研究型医院泌尿外科青年委员会副主任委员、北京健康促进会泌尿外科专业委员会委员。

代表性文章 (#第一作者; *通讯作者)

厂颁滨文章

1. He A, He S, Huang C, ... Li X* et al. MTDH promotes metastasis of clear cell renal cell carcinoma by activating SND1-mediated ERK signaling and epithelial-mesenchymal transition. Aging (Albany NY). 2020;12(2):1465-1487. (IF 4.831)

2. Zhan Y, Chen Z, He S, ... Li X* et al. Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2. Mol Cancer. 2020;19(1):25. (IF 15.302)

3. Xiong S, Zhu W, Li X, Zhang P, Wang H, Li X*. Intestinal interposition for complex ureteral reconstruction: A comprehensive review. Int J Urol. 2020;27(5):377-386. (IF 2.445)

4. Lu H, Liang Y, Guan B, ... Li X* et al. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma. Theranostics. 2020;10(10):4323-4333. (IF 8.579)

5. Wang J, Xiong S, Fan S, ... Li X * et al. Appendiceal Onlay Flap Ureteroplasty for the Treatment of Complex Ureteral Strictures: Initial Experience of Nine Patients. J Endourol. 2020;34(8):874-881. (IF 2.322)

6. Ji G, Huang C, He S, ... Li X* et al. Comprehensive analysis of m6A regulators prognostic value in prostate cancer. Aging (Albany NY). 2020;12(14):14863-14884. (IF 4.831)

7. Xiong S, Wang J, Zhu W, ... Li X * et al. Onlay Repair Technique for the Management of Ureteral Strictures: A Comprehensive Review. Biomed Res Int. 2020; 2020:6178286. (IF 2.276)

8. Fan S, Yin L, Yang K, ... Li X * et al. Posteriorly augmented anastomotic ureteroplasty with lingual mucosal onlay grafts for long proximal ureteral strictures: Ten cases of experience. J Endourol. 2020. (IF 2.322)

9. Cheng S, Fan S, Wang J, ... Li X* et al. Laparoscopic and robotic ureteroplasty using onlay flap or graft for the management of long proximal or middle ureteral strictures: our experience and strategy[J]. International Urology and Nephrology, 2020(7):1-10. (IF 1.843)

10. Bao Guan #, Shiying Tang #, Yonghao Zhan #, Yifan Li, Dong Fang, Ding Peng, Yanqing Gong, Shiming He, Lei Zhang, Kunlin Yang, Gengyan Xiong, Libo Liu, Qun He, Xuesong Li*, Liqun Zhou*. Prognostic performance of the 1973 and 2004 WHO grading classification in upper tract urothelial carcinoma. Urol Oncol. 2019. (IF 3.397)

11. Yifan Li #, Bao Guan #, Jingtao Liu #, Zhongyuan Zhang, Shiming He, Yonghao Zhan, Boxing Su, Haibo Han, Xiaochun Zhang, Boqing Wang, Xuesong Li*, Liqun Zhou*, Wei Zhao*. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma. EBioMedicine. 2019. (IF 6.183)

12. Yifan Li#, Shiming He#, Anbang He, Bao Guan, Guangzhe Ge, Yonghao Zhan, Yucai Wu, Yanqing Gong, Ding Peng, Zhengqing Bao, Xuesong Li*, Liqun Zhou*. Identification of plasma secreted phosphoprotein 1 as a novel biomarker for upper tract urothelial carcinomas. Biomed Pharmacother. 2019; 113: 108744. (IF 3.457)

13. Wenlong Zhong#, Peng Hong#, Guangpu Ding#, Kunlin Yang, Xuesong Li*, Junsheng Bao, Guochang Bao,Liang Cui, Changping Men, Zhe Li, Peng Zhang, Ning Chu and Liqun Zhou*. Technical considerations and outcomes for ileal ureter replacement: a retrospective study in China. BMC Surgery, 2019; 19:9. (IF 1.692)

14. Peng Hong#, Ziao Li#, Dongdong Zhu#, Liyan Zhuang, Kunlin Yang, Han Hao, Xuesong Li*, Liqun Zhou*. A Simple Modification for the Usage of Flexible Cystoscope in Modified Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction with Renal Calculi: A Flexible Guiding Tube. Urol Int. 2019;102(3):262-268. (IF 1.508)

15. Yifan Li#, Dong Fang#, Zhengqing Bao#, Anbang He, Bao Guan, Shiming He, Yonghao Zhan, Yanqing Gong, Xuesong Li*, Liqun Zhou*. High aspartate transaminase/alanine transaminase ratio predicts poor prognosis in patients with localized upper tract urothelial cancer: a propensity score-matched study in a large Chinese center. OncoTargets Ther, 2019;12:2635-2648. (IF 2.656)

16. Peng Hong, Yukun Cai, Ziao Li, Shubo Fan, Kunlin Yang, Han Hao, Qun He, Xuesong Li*, Liqun Zhou*. Modified Laparoscopic Partial Ureterectomy for Adult Ureteral Fibroepithelial Polyp: Technique and Initial Experience. Urol Int. 2018;102(1):13-19. (IF 1.508)

17. Zhuo Jia#, Yanqing Gong#, Cuijian Zhang, Zhengqing Bao, Xuesong Li*, Han Hao, Gengyan Xiong, Lei Zhang, Dong Fang, Zhisong He, Liqun Zhou*. Segmental ureterectomy can be performed safely in patients with urothelial carcinoma of distal ureter. Can Urol Assoc J. 2018;13(7). (IF 1.179)

18. Yifan Li#, Yanqing Gong#, Xianghui Ning, Ding Peng, Libo Liu, Shiming He, Kan Gong, Cuijian Zhang*, Xuesong Li* and Liqun Zhou*. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. J Exp Clin Cancer Res. 2018;37(1):276. (IF 6.217)

19. Yonghao Zhan, Zhicong Chen, Yifan Li, Anbang He, Shiming He, Yanqing Gong, Xuesong Li* and Liqun Zhou*. Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J Exp Clin Cancer Res. 2018;37(1):273. (IF 6.217)

20. Anbang He#, Shiming He#, Xuesong Li*, Liqun Zhou*. ZFAS1: A novel vital oncogenic lncRNA in multiple human cancers. Cell Proliferation. 2018;66(4): e12513. (IF 4.936)

21. Ding Peng, Guangzhe Ge, Zhengzheng Xu, Qin Ma, Yue Shi, Yuanyuan Zhou, Yanqing Gong, Gengyan Xiong, Cuijian Zhang, Shiming He, Zhisong He, Xuesong Li*, Weimin Ci* and Liqun Zhou*. Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation. Epigenomics. 2018;10(9):1189-1199. (IF 4.979)

22. Zhicong Chen#, Yonghao Zhan#, Jieshan Chi#, Shuyuan Guo#, Xinliang Zhong, Anbang He, Jianrong Zheng, Yanqing Gong, Xuesong Li*, Liqun Zhou*. Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis. EBioMedicine. 2018; 34:94-107. (IF 6.183)

23. Guangzhe Ge#, Ding Peng#, Ziying Xu#, Bao Guan, Zijuan Xin, Qun He, Yuanyuan Zhou, Xuesong Li*, Liqun Zhou* and Weimin Ci*. Restoration of 5-hydroxymethylcytosine by ascorbate blocks kidney tumour growth. EMBO Reports. 2018;19(8): e45401. (IF 8.749)

24. Ding Peng, Guangzhe Ge, Yanqing Gong, Yonghao Zhan, Shiming He, Bao Guan, Yifan Li, Ziying Xu, Han Hao, Zhisong He Gengyan Xiong, Cuijian Zhang, Yue Shi, Yuanyuan Zhou, Weimin Ci*, Xuesong Li* and Liqun Zhou*. Vitamin C increases 5-hydroxymethylcytosine level and inhibits the growth of bladder cancer. Clin Epigenetics. 2018;10(1):94. (IF 6.091)

25. Bao Guan#, Yunchao Xing#, Gengyan Xiong#, Zhenpeng Cao, Dong Fang, Yifan Li, Yonghao Zhan, Ding Peng, Libo Liu, Xuesong Li* and Liqun Zhou*. Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper-tract urothelial carcinoma. Oncology Letters. 2018;15(6):9397-9405. (IF 1.664)

26. Ding Peng#, Cuijian Zhang#, Yanqing Gong*, Han Hao, Bao Guan, Xuesong Li* and Liqun Zhou*. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Scientific Reports. 2018; 8:794. (IF 4.122)

27. Ding Peng#, Cui-jian Zhang#, Qi Tang, Lei Zhang, Kai-wei Yang, Xiao-teng Yu, Yanqing Gong, Xue-song Li*, Zhi-song He and Li-qun Zhou*. Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy. BMC Urol, 2018, 18:20. (IF 1.792)

28. Dong Fang#, Shiming He#, Gengyan Xiong#, Nirmish Singla, Zhenpeng Cao, Lei Zhang, Xuesong Li* and Liqun Zhou*. Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma. BMC Urol. 2018;18(1):22. (IF 1.792)

29. Bao Guan#, Yicong Du#, Xiaohong Su#, Zhenpeng Cao, Yifan Li, Yonghao Zhan, Ding Peng, Gengyan Xiong, Dong Fang, Yi Ding, Shiming He, Yanqing Gong, Qun He, Xuesong Li* and Liqun Zhou*. Positive urinary fluorescence in situ hybridization indicates poor prognosis in patients with upper tract urothelial carcinoma. Oncotarget. 2018;9(18):14652-14660.

30. Run-Qi Guo#, Geng-Yan Xiong#, Kai-Wei Yang, Lei Zhang, Shi-Ming He, Yan-Qing Gong, , Qun He, Xue-Ying Li, Zi-Cheng Wang, Zhen-Qing Bao, Xue-Song Li*, Kai Zhang, Li-Qun Zhou*. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. Urol Oncol. 2018; 36(7): 342.e15-342.e23. (IF 3.397)

31. Shiying Tang, Han Hao, Dong Fang, Wei Zheng, Peng Ge, Xiaohong Su, Qun He, Xinyu Yang , Qi Shen, Xuesong Li*, Wei Yu, Jian Lin, Liqun Zhou. Prostate cancer incidentally discovered at the time of radical cystoprostatectomy does not decrease overall survival: Results from a large Chinese medical center. Int Braz J Urol. 2018;44(2):258-266. (IF 0.976)

32. Peng Hong, Guangpu Ding, Dongdong Zhu, Kunlin Yang, Jinhong Pan*, Xuesong Li*, Zhipeng Chen, Lei Zhang, Qi Tang, Han Hao, Zhansong Zhou and Liqun Zhou. Head-to-Head Comparison of Modified Laparoscopic Pyeloplasty and Robot-Assisted Pyeloplasty for Ureteropelvic Junction Obstruction in China. Urol Int. 2018; 101(3):337-344. (IF 1.508)

33. Gengyan Xiong#, Lin Yao#, Peng Hong#, Li Yang, Weimin Ci, Libo Liu, Qun He, Kan Gong, Xuesong Li* and Liqun Zhou*. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. Cancer Manag Res. 2018;10: 6627-6639. (IF 3.702)

34. Wenlong Zhong#, Lin Yao#, Haoran Cui, Kunlin Yang, Gang Wang, Tao Xu, Xiongjun Ye, Xuesong Li*, Liqun Zhou*. Laparoscopic ureteral reimplantation with extracorporeal tailoring and direct nipple ureteroneocystostomy for adult obstructive megaureter: long-term outcomes and comparison to open procedure. Int Urol Nephrol. 2017;49(11):1973-1978. (IF 1.692)

35. Shiying Tang#, Guochen Niu#, Dong Fang, Ziguang Yan, Bihui Zhang, Xuesong Li*, Min Yang*, Liqun Zhou*. The diagnosis and endovascular therapy of renal artery aneurysm: A 32-patient case report. Medicine (Baltimore). 2017;96(47): e8615. (IF 2.028)

36. Wenlong Zhong#, Yicong Du#, Kunlin Yang, Steven Meng, Rongcheng Lin, Xuesong Li*, Liyan Zhuang, Lin Cai, Haoran Cui, Zhisong He, and Liqun Zhou. Ileal Ureter Replacement Combined with Boari Flap-Psoas Hitch to Treat Full-Length Ureteral Defects: Technique and Initial Experience. Urology. 2017;108: 201-206. (IF 2.3)

37. ZhenPeng Cao, Bao Guan, GuangZhi Zhao, Dong Fang, GengYan Xiong, Xuesong Li*, LiQun Zhou. Validation of the Pretreatment NeutrophiltoLymphocyte Ratio as a Prognostic Factor in a Large Cohort of Chinese Patients with Upper Tract Urothelial Carcinoma. Chin Med J (Engl). 2017, 130(17):2063-2068. (IF 1.596)

38. Yonghao Zhan, Yifan Li, Bao Guan, Zicheng Wang, Ding Peng, Zhicong Chen, Anbang He, Shiming He, Yanqing Gong, Xuesong Li* and Liqun Zhou*. Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2. Oncotarget. 2017;8(44):76656-76665. (IF 5.168)

39. Yonghao Zhan#, Yifan Li#, Bao Guan#, Xiaoying Chen, Zhicong Chen, Anbang He, Shiming He, Yanqing Gong, Ding Peng, Yuchen Liu, Zhiming Cai, Xuesong Li* and Liqun Zhou*. Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. Oncotarget. 2017;8(27):44326-44334. (IF 5.168)

40. Xiaohong Su#, Han Hao#, Xuesong Li*, Zhisong He, Kan Gong, Cuijian Zhang, Lin Cai, Qian Zhang, Lin Yao, Yi Ding, Yanqing Gong, Dong Fang, Zheng Zhang and Liqun Zhou*. Fluorescence in situ hybridization status of voided urine predicts invasive and high-grade upper tract urothelial carcinoma. Oncotarget. 2017;8(16):26106-26111. (IF 5.168)

41. Wenlong Zhong#, Rongcheng Lin#, Lei Zhang, Chengyue Jin, Xuesong Li*, Qun He, Kan Gong, Zhisong He, Liqun Zhou*. Clinicopathologic characteristics, therapy and outcomes of patients with primary ureteral small cell carcinoma: a case series and systematic review of the literature. OncoTargets Ther. 2017; 10:4105-4111. (IF 2.656)

42. Wenlong Zhong#, Lei Zhang#, Jiajian Ma, Shan Shao, Rongcheng Lin, Xuesong Li*, Gengyan Xiong, Dong Fang, Liqun Zhou*. Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. OncoTargets Ther. 2017; 10:5775-5782. (IF 2.656)

43. Wenlong Zhong, Yicong Du, Lei Zhang, Xuesong Li*, Cuijian Zhang, Dong Fang, Gengyan Xiong, Zhisong He, and Liqun Zhou*. The Application of Internal Suspension Technique in Retroperitoneal Laparoscopic Partial Nephrectomy for Renal Ventral Tumors. BioMed Res Int. 2017;2017(5i):1-7. (IF 2.583)

44. Yunchao Xing#, Gengyan Xiong#, Dong Fang, Xinyu Yang, Xuesong Li*, Liqun Zhou*. Prognostic Value of Gene Methylation and Clinical Factors in Non-Muscle-Invasive Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. Clin Genitourin Cancer. 2016;14(4): e371-e378. (IF 2.539)

45. Pei Liu, Xiaohong Su, Gengyan Xiong, Xuesong Li*, Liqun Zhou. Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma is Independently Associated with Intravesical Recurrence after Radical Nephroureterectomy. Int Braz J Urol. 2016; 42 (6): 1129-1135. (IF 0.976)

46. Xiaohong Su#, Dong Fang#, Lei Zhang, Gengyan Xiong, Han Hao, Guangzhi Zhao, Kunlin Yang, Yunchao Xing, Xuesong Li*, Liqun Zhou*. Treatment strategies for upper tract urothelial carcinoma (UTUC) of a solitary kidney: a single-institutional analysis of 61 cases. Int Urol Nephrol. 2016;48(10):1601-1608. (IF 1.692)

47. Lei Zhang, Dong Fang, Xuesong Li*, Lin Yao, Gengyan Xiong, Zhisong He, and Liqun Zhou*. Transperitoneal Subcostal Access for Urologic Laparoscopy: Experience of a Large Chinese Center. BioMed Res Int. 2016;2016(1):1-5. (IF 2.583)

48. Xiaohong Su, Dong Fang, Xuesong Li*, Gengyan Xiong, Lei Zhang, Han Hao, Yanqing Gong, Zheng Zhang, and Liqun Zhou*. The Influence of Tumor Size on Oncologic Outcomes for Patients with Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy. BioMed Res Int. 2016; 2016:1-7. (IF 2.583).

49. Lei Zhang, Lin Yao, Xuesong Li*, Michael A.S. Jewett, Zhisong He, Liqun Zhou*. Natural history of renal cell carcinoma: An immunohistochemical analysis of growth rate in patients with delayed treatment. J Formos Med Assoc. 2015;115(6):463-469. (IF 2.452)

50. Qi Tang#, Gengyan Xiong#, Xuesong Li*, Dong Fang, Chenguang Xi, Lei Zhang, Kaiwei Yang, Lin Yao, Cuijian Zhang, Wei Yu, Qun He, Kan Gong, Zhisong He, Liqun Zhou*. The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy. World J Urol. 2015;34(6):871-877. (IF 2.981)

51. Pei Liu#, Dong Fang#, Gengyan Xiong, Kaiwei Yang, Lei Zhang, Lin Yao, Cuijian Zhang, Xuesong Li*, Zhisong He, Liqun Zhou*. A Novel and Simple Modification for Management of Distal Ureter During Laparoscopic Nephroureterectomy Without Patient Repositioning: A Bulldog Clamp Technique and Description of Modified Port Placement. J Endourol. 2015;30(2):195-200. (IF 2.038)

52. Dong Fang#, Pei Liu#, Xuesong Li*, Gengyan Xiong, Lei Zhang, Nirmish Singla, Guangzhi Zhao, Qun He, Zhisong He and Liqun Zhou*. Characteristics and treatment outcomes of pan-urothelial cell carcinoma: a descriptive analysis of 45 patients. Scientific Reports. 2015;5(1):18014. (IF 4.122)

53. Yanqing Gong, Wei Qiu, Xianghui Ning, Xinyu Yang, Libo Liu, Zicheng Wang, Jian Lin, Xuesong Li*, Yinglu Guo*. CCDC34 is up-regulated in bladder cancer and regulates bladder cancer cell proliferation, apoptosis and migration. Oncotarget. 2015; 6(28): 25856-25867. (IF 5.168)

54. Kunlin Yang#, Lin Cai#, Lin Yao, Zheng Zhang, Cuijian Zhang, Xin Wang, Jianqiang Tang*, Xuesong Li*, Zhisong He and Liqun Zhou. Laparoscopic total pelvic exenteration for pelvic malignancies: the technique and short-time outcome of 11 cases. World J Surg Oncol. 2015;13(1):301. (IF 1.792)

55. Zheng Zhang#, Dong Fang#, Xiaopeng Chen, Xuesong Li*, Gengyan Xiong, Lei Zhang, Qun He and Liqun Zhou*. Predictive role of preoperative hydronephrosis on poor pathological outcomes and prognosis in upper tract urothelial carcinoma patients: Experience from a nationwide high-volume center in China. Oncol Lett. 2015;10(5):3113-3122. (IF 1.664)

56. Xiaoteng Yu#, Gang Guo#, Xuesong Li#, Cuijian Zhang, Lihua Huang, Dong Fang, Yi Song, Xu Zhang, and Liqun Zhou*. Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients with Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival. Medicine (Baltimore). 2015;94(34): e1361. (IF 2.028)

57. Lei Zhang, Xuesong Li*, Liqun Zhou*. Natural History of Small Renal Masses. Chin Med J (Engl). 2015; 128(9): 1232–1237. (IF 1.596)

58. Gengyan Xiong#, Jin Liu#, Qi Tang, Yu Fan, Dong Fang, Kaiwei Yang1, Feng Xie, Min Zhang, Lei Zhang, Libo Liu, Cuijian Zhang, Lin Yao, Li Yang, Weimin Ci, Wei Zhao, Yanqing Gong, Qun He, Kan Gong, Zhisong He, Gang Wang, Xuesong Li*, Yinglu Guo and Liqun Zhou#. Prognostic and predictive value of epigenetic biomarkers and clinical factors in upper tract urothelial carcinoma. Epigenomics. 2015;7(5):733-744. (IF 4.979)

59. Dong Fang#, Lei Zhang#, Xuesong Li*, Wei Yu, Nirmish Singla, Guangzhi Zhao, Gengyan Xiong, Yi Song, Qun He, Zhisong He, and Liqun Zhou*. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value. Ann Surg Oncol. 2015;22(8):2789-2798. (IF 3.857)

60. Bentao Shi#, Boxing Su#, Dong Fang, Yuan Tang, Gengyan Xiong, Zhongqiang Guo, Qun He, Xinyu Yang, Wei Zhao, Yinglu Guo, Xuesong Li* and Liqun Zhou*. High expression of KPNA2 defines poor prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. BMC Cancer. 2015;15(1):380. (IF 3.288)

61. Dong Fang#, Gengyan Xiong#, Xuesong Li*, Yongming Kang, Lei Zhang, Guangzhi Zhao, Xiaopeng Chen, Lin Yao, Xiaoyu Zhang, Wei Yu, Kan Gong, Yi Song, Qun He, Zhisong He, Liqun Zhou*, Yinglu Guo. Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population. Urologic Oncology. 2015;33(2): 66.e1-.e11. (IF 3.397)

62. Lei Zhang#, Gengyan Xiong#, Dong Fang, Xuesong Li*, Jin Liu, Weimin Ci, Wei Zhao, Nirmish Singla, Zhisong He and Liqun Zhou*. Contralateral upper tract urothelial carcinoma after nephroureterectomy: the predictive role of DNA methylation. J Exp Clin Cancer Res. 2015;34(1):5. (IF 6.217)

63. Kunlin Yang#, Lin Yao#, Xuesong Li*, Cuijian Zhang, Tianyu Wang, Lei Zhang, Dong Fang, Zhisong He, and Liqun Zhou*. A modified suture technique for transperitoneal laparoscopic dismembered pyeloplasty of pelviureteric junction obstruction. Urology. 2015;85(1):263-267. (IF 2.3)

64. Lei Zhang, Wenshi Yin, Lin Yao, Xuesong Li*, Dong Fang, Da Ren, Zhongyuan Zhang, Yu Fan, Qun He, Weimin Ci, Zhisong He, and Liqun Zhou*. Growth Pattern of Clear Cell Renal Cell Carcinoma in Patients with Delayed Surgical Intervention: Fast Growth Rate Correlates with High Grade and May Result in Poor Prognosis. BioMed Res Int. 2015;2015(4):598134-598138. (IF 2.583)

65. Qi Tang, Yi Song, Xuesong Li*, Maxwell Meng, Qian Zhang, Jin Wang, Zhisong He, and Liqun Zhou*. Prognostic Outcomes and Risk Factors for Patients with Renal Cell Carcinoma and Venous Tumor Thrombus after Radical Nephrectomy and Thrombectomy: The Prognostic Significance of Venous Tumor Thrombus Level. BioMed Res Int. 2015; 2015:163423. (IF 2.583)

66. Xiaoteng Yu, Bing Wang, Xuesong Li*, Gang Lin, Cuijian Zhang, Yang Yang, Dong Fang, Yi Song, Zhisong He and Liqun Zhou*. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. BioMed Res Int. 2015; 2015:176373. (IF 2.583)

67. Zhongqiang Guo, Jin Liu, Lian Zhang, Boxing Su, Yunchao Xing, Qun He, Weimin Ci, Xuesong Li* and Liqun Zhou*. KCNJ1 inhibits tumor proliferation and metastasis and is a prognostic factor in clear cell renal cell carcinoma. Tumour Biol. 2014;36(2):1251-1259. (IF 3.65)

68. Dong Fang#, Lei Zhang#, Xuesong Li*, Gengyan Xiong, Xiaopeng Chen, Wenke Han, Zhisong He, Liqun Zhou*. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J Cancer Res Clin Oncol. 2014;140(3):477-485. (IF 3.282)

69. Dong Fang, Qifu Zhang, Xuesong Li*, Cheng Qian, Gengyan Xiong, Lei Zhang, Xiaopeng Chen, Xiaoyu Zhang, Wei Yu, Zhisong He, and Liqun Zhou*. Nomogram predicting renal insufficiency after nephroureterectomy for upper tract urothelial carcinoma in the Chinese population: exclusion of ineligible candidates for adjuvant chemotherapy. BioMed Res Int. 2014; 2014(3): 529186-10. (IF 2.583)

70. Xuesong Li*, Dong Fang, Matthew R. Cooperberg*, Jared M. Whitson, Tom F. Lue, Liqun Zhou, Katsuto Shinohara. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol. 2013;32(4):1061-1066. (IF 2.981)

71. Gengyan Xiong, Xiaopeng Chen, Xuesong Li*, Dong Fang, Luxia Zhang, Li Yang, Lei Zhang, Lin Yao, Zhisong He, Liqun Zhou*. Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients. J Formos Med Assoc. 2013;113(8):521-526. (IF 2.452)

72. Rui He#, Wei Yu#, Xuesong Li*, Lin Yao, Zhisong He, and Liqun Zhou*. Laparoscopic ureteral reimplantation with extracorporeal tailoring and direct nipple ureteroneocystostomy for adult obstructed megaureter: a novel technique. Urology. 2013;82(5):1171-1174. (IF 2.3)

73. Xue-Song Li#, Lin Yao, Kan Gong, Wei Yu, Qun He, Li-Qun Zhou, Zhi-Song He*. Growth pattern of renal cell carcinoma (RCC) in patients with delayed surgical intervention. J Cancer Res Clin Oncol. 2012; 138:269–274. (IF 3.282)

74. Hongjian Zhu, Cheng Shen, Xuesong Li*, Xuren Xiao, Xianglong Chen, Qingjiang Zhang, Hua Wang, Zhisong He, Liqun Zhou. Laparoscopic pyeloplasty: a comparison between the transperitoneal and retroperitoneal approach during the learning curve. Urol Int. 2012;90(2):130-135. (IF 1.508)

75. Cuijian Zhang, Xuesong Li*, Han Hao, Wei Yu, Zhisong He and Liqun Zhou*. The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases. BJU Int. 2012;110(11 Pt B): E481-E485. (IF 4.688)

76. Cuijian Zhang, Xuesong Li*, Zhisong He, Yunxiang Xiao, Shuqing Li, and Liqun Zhou. Squamous cell carcinoma of the enlarged prostatic utricle in an adult. Urology. 2012;79(2):e23-e24. (IF 2.3)

77. Xiaopeng Chen, Xuesong Li*, Maurice M. Garcia, Kan Gong, Yi Song, Zhisong He, and Liqun Zhou*. Prognostic factors in Chinese patients with penile invasive squamous cell carcinoma. J Androl. 2012;33(6):1276-1281.

78. Rui He, Xinyu Yang, Xuesong Li*, Zhisong He, and Liqun Zhou. Cystic schwannoma of a seminal vesicle. J Androl. 2012;33(5):798-800.

79. Wei Zheng, Xuesong Li*, Gang Song, Zheng Zhang, Wei Yu, Kan Gong, Yi Song, Qian Zhang, Zhisong He, Yinglu Guo, Liqun Zhou*. Comparison of laparoscopic and open cystectomy for bladder cancer: a single center of 110 cases report. Transl Androl Urol. 2012;1(1):4-8.

中文文章

1. 杨昆霖,李晓颖,李学松*，周利群.术后辅助放疗在上尿路尿路上皮癌治疗中的应用现状[J].中华泌尿外科杂志,2020,41(5):394-396.

2. 李新飞，程嗣达，孙永明，杨昆霖，张雷，李志华，贯华，黄燕波，郝瀚，李学松*，周利群.机器人辅助腹腔镜回肠膀胱扩大术治疗结核性膀胱挛缩的初步经验[J]. 临床泌尿外科杂志, 2020(8):610-614.

3. 程嗣达,李新飞,熊盛炜,樊书菠,王杰,朱伟杰,李子奡,丁光璞,俞婷,李万强,孙永明,杨昆霖,张雷,郝瀚,李学松*,周利群. 机器人辅助腹腔镜上尿路修复手术：单一术者108例经验总结[J]. 北京大学学报(医学版) 2020, 52(4):771-779.

4. 黄炳伟,王杰,张鹏,李喆,毕泗成,王强,岳才博,杨昆霖,李学松*,周利群. 吲哚菁绿在复杂上尿路修复手术中的应用[J]. 北京大学学报:医学版, 2020(4):651-656.

5. 熊盛炜，王杰，朱伟杰，程嗣达，张雷，李学松*，周利群.二次肾盂成形术在复发性肾盂输尿管连接部梗阻中的研究进展[J]. 北京大学学报(医学版)，2020年4期。

6. 郑蒙蒙,彭意吉,朱伟杰,杨昆霖,丁光璞,关豹,张磊,张进生,李学松*,周利群.三维影像重建测量积水肾体积参数在评估肾功能中的应用[J].现代泌尿外科杂志，2020,25(2):116-120

7. 郑蒙蒙，丁光璞，朱伟杰，杨昆霖，樊书菠，关豹，李新飞，蔡宇坤，张进生，李学松*，周利群.术前三维影像重建在治疗肾盂输尿管连接部梗阻中的应用[J].北京大学学报(医学版),2020,52(4):705-710.

8. 李世强,智静涛,武利兵,张锋,吴宪伟,李学松*.内镜治疗前列腺增生与尿道狭窄后并发感染的临床特征与治疗效果研究[J].中国性科学,2019,28(2):27-29.

9. 李学松#,洪鹏,丁光璞, 等.经腹完全腹腔镜肾输尿管全长切除术的关键技术总结(附光盘)[J].现代泌尿外科杂志,2018,23(10):728-731.

10. 鲍正清#,方冬#,纪永鹏,李学松*,周利群*.阴茎癌腹股沟淋巴结清扫腹腔镜手术的新进展[J].现代泌尿外科杂志,2018,23(4):309-312,316.

11. 余霄腾,张崔建,彭鼎,林榕城,唐琦,杨恺惟,张争,何志嵩,李学松*,周利群*.系统免疫炎症指数对于肾透明细胞癌患者术后预后的意义[J].中华临床医师杂志(电子版),2018,12(9):483-487.

12. 钟文龙,李学松*,周利群*.内部悬吊技术在腹侧肾肿瘤后腹腔镜下肾部分切除术中的应用[J].微创泌尿外科杂志,2017,6(5):

13. 关豹,曹振朋,彭鼎, 李一帆,詹永豪,何世明,巩艳青,方冬,张雷,熊耕砚,李学松*,周利群*.上尿路尿路上皮癌患者膀胱复发灶的危险因素分析[J].中华泌尿外科杂志,2017,38(12):896-900.

14. 曹振朋,关豹,方冬, 熊耕砚,何世明,李学松*,周利群.年轻上尿路尿路上皮癌患者的临床病理和预后特征[J].现代泌尿外科杂志,2017,22(9):661-665.

15. 唐世英,郝瀚,方冬, 郑卫,彭东,詹永豪,鲍正清,李学松*,周利群*.保留女性生殖器官膀胱切除术的临床预后分析(附87例报告)[J].临床泌尿外科杂志,2017,32(10):741-745,750.

16. 关豹,曹振朋,彭鼎, 李一帆,詹永豪,刘漓波,何世明,熊耕砚, 李学松*,周利群*.T2N0M0期上尿路尿路上皮癌患者预后相关因素分析:单中心235例患者回顾性研究[J].北京大学学报(医学版),2017,49(4):603-607.

17. 洪鹏,李一帆,方冬,,郭润碛,钟文龙,郝 瀚,郑 卫,葛 鹏,巩艳青,张 争*,李学松*,林 健,周利群.体质指数对于根治性膀胱全切患者的临床特征和治疗结局的影响[J].肿瘤学杂志,2017,23(7):567-573.

18. 朱雨泽,张雷,方冬,李学松*,周利群*.双肾嗜酸细胞瘤1例报告并文献复习[J].现代泌尿外科杂志,2016,21(9):734-735.

19. 刘瑾,熊耕砚,唐琦,方冬,李学松*,周利群*.上尿路尿路上皮癌中 RASSF1A 基因启动子区域的甲基化状态及其临床意义[J].北京大学学报(医学版),2016,48(4):571-578.

20. 苏晓鸿,方冬,张雷,熊耕砚, 郝瀚,赵广智,杨昆霖,李学松*,周利群*.孤立肾上尿路尿路上皮癌61例临床诊疗分析[J].临床泌尿外科杂志,2016,31(12):1078-1082,1087.

21. 邢云超,熊耕砚,方东,张争,蔡林,张雷,何志嵩,李学松*,周利群*.上尿路尿路上皮癌术前预后相关因素分析及初步风险分层模型构建[J].北京大学学报(医学版),2016,48(6):1032-1037.

22. 钟文龙#,郝瀚#,苏晓鸿, 方冬,郑卫,葛鹏,李学松*,周利群*.根治性膀胱全切术后患者临床病理及预后的性别差异(附427例报告)[J].临床泌尿外科杂志,2016,31(11):974-978.

23. 姬超岳#,钟文龙#,张雷, 张雷,李学松*,方冬,郝瀚,熊耕砚,周利群*.上尿路上皮癌根治术后对侧上尿路复发危险因素分析[J].临床泌尿外科杂志,2016,31(11):965-968,973.

24. 鲍正清#,方冬#,岳才博,岳才博,蔡 林,王天昱,李学松*,周利群*.原发性阴茎阴囊 Paget 病22例临床分析[J].北京大学学报(医学版),2016,48(4):638-642.

25. 张雷,邓文涛,李学松*, 等.高度怀疑恶性前列腺肿物6针法穿刺临床分析[J].现代泌尿外科杂志,2016,21(10):786-789.

26. 彭鼎#,李学松#,张崔建, 等.T3 N0 M0期肾细胞癌患者预后相关因素分析：单中心182例患者回顾性研究[J].北京大学学报(医学版),2016,48(5):806-811.

27. 张华俊#,唐世英#,张中元,唐 琦,李学松*,周利群*.肾部分切除术术前肾周脂肪粘连的评估[J].现代泌尿外科杂志,2016,21(9):727-729.

28. 钟文龙,杨昆霖,李学松*, 等.回肠代输尿管术治疗双侧长段输尿管损伤一例报告并文献复习[J].中华泌尿外科杂志,2016,37(8):599-602

29. 李学松#,钟文龙,吴帅, 等.回肠代输尿管术临床应用及手术技巧(附光盘)[J].现代泌尿外科杂志,2016,21(4):245-248. DOI:10.3969/j.issn.1009-8291.2016.04.001.

30. 余霄腾,张崔建,李学松*, 等.索拉非尼治疗晚期肾癌患者的疗效及不良反应[J].现代泌尿外科杂志,2016,21(6):437-440.

31. 曹振朋,刘瑾,李学松*.马兜铃酸相关尿路上皮癌研究进展[J].中华泌尿外科杂志,2015,36(8):638-640.

32. 李学松*,刘沛.腹腔镜及开放根治性膀胱全切-回肠原位新膀胱术的比较及应用体会[J].中华腔镜泌尿外科杂志(电子版),2015,(2):81-85.

33. 郭刚#,李学松#,张帆, 等.索拉非尼治疗晚期肾癌所致手足皮肤反应与疗效的相关性研究[J].临床泌尿外科杂志,2015,30(10):893-896.

34. 杨昆霖,李学松*,周利群*.IUPU经腹腹腔镜联合膀胱软镜肾盂取石及肾盂成型术[J].泌尿外科杂志(电子版),2015,(3):4-6.

35. 28. 刘沛,李学松*,周利群*.经腹完全腹腔镜肾输尿管全长切除术及改良膀胱袖状切除术：滨鲍笔鲍技术[J].泌尿外科杂志(电子版),2015,(3):10-12,6.

36. 29. 唐琦,李学松*,周利群*.联合腹膜后及经腹入路腹腔镜治疗肾癌伴下腔静脉瘤栓[J].泌尿外科杂志(电子版),2015,(3):1-3.

37. 杨昆霖,李学松*,周利群*.IUPU经腹腹腔镜巨输尿管体外裁剪、乳头再植术[J].泌尿外科杂志(电子版),2015,(3):7-9.

38. 李学松#,周利群*,唐琦, 等.联合后腹腔及经腹入路腹腔镜技术在肾癌伴下腔静脉瘤栓患者中的应用[J].北京大学学报(医学版),2015,47(4):569-570.

39. 吴鑫,刘沛,朱雨泽,郑 卫,唐 琦,姚 林,张崔建,郝 瀚,李学松*,周利群.腹腔镜与开放根治性膀胱全切-回肠原位新膀胱术的疗效对比[J].现代泌尿外科杂志,2015,(4):229-233.

40. 李学松#,杨昆霖,周利群.IUPU经腹腹腔镜肾盂成型术治疗成人肾盂输尿管连接处梗阻(附视频)[J].现代泌尿外科杂志,2015,(6):369-372.

41. 刘沛#,吴鑫#,朱雨泽,唐琦,方冬,李学松*,郝金瑞,周利群*.回肠代输尿管术治疗医源性长段输尿管损伤[J].北京大学学报(医学版),2015,47(4):643-647.

42. 刘沛,李学松*.嗜铬细胞瘤应行腹腔镜手术治疗[J].现代泌尿外科杂志,2014,19(10):683-685.

43. 张雷,李学松*.T1b期肾癌应选择肾根治术[J].现代泌尿外科杂志,2014,(12):821-822. DOI:10.3969/j.issn.1009-8291.2014-12-016.

44. 周亮亮,陈玉成,李学松*.膀胱嗜铬细胞瘤的诊治体会[J].首都医药,2014,(10):29-29,30.

45. 杨昆霖,李学松*,周利群*.经腹腹腔镜输尿管体外裁剪、乳头再植术治疗成人梗阻性巨输尿管症的方法[J].北京大学学报(医学版),2014,46(4):511-514.

46. 杨恺惟,张崔建,李学松*, 等.小肾癌的临床病理特征:单中心1276例经验总结[J].北京大学学报(医学版),2014,46(5):790-793.

47. 康永明,方冬,李学松*, 等.双侧上尿路尿路上皮癌30例临床诊疗分析[J].首都医科大学学报,2014,(3):290-294.

48. 刘沛,唐琦,李学松*, 等.女性原发性尿道癌8例临床分析[J].现代泌尿外科杂志,2014,19(10):662-665,669.

49. 张雷,姚林,李学松*, 等.经腹腹腔镜肾切除手术的肾蒂处理技术:单一术者191例经验总结[J].北京大学学报(医学版),2014,46(4):537-540.

50. 李学松#.经腹腹腔镜肾癌根治术的肾蒂处理经验:手术技巧及出血性并发症的腔镜下处理(附视频)[J].现代泌尿外科杂志,2013,18(1):6-8,12.

51. 姚林,李学松*.肾脏小肿物的自然病程及诊治进展[J].中华泌尿外科杂志,2013,34(11):875-878.

52. 杨恺惟,李学松*,周利群.肾脏黏液小管状和梭形细胞癌一例并文献回顾[J].中华临床医师杂志(电子版),2013,(8):3652-3654. DOI:10.3877/cma.j.issn.1674-0785.2013.08.080.

53. 方冬,李学松*.腹腔镜上尿路手术经腹腔途径更有优势[J].现代泌尿外科杂志,2013,18(2):183-185. DOI:10.3969/j.issn.1009-8291.2013.02.028.

54. 郑卫,汤坚强,李学松*.盆腔胸膜外孤立性纤维性肿瘤一例报告[J].中华泌尿外科杂志,2013,34(1):77. DOI:10.3760/cma.j.issn.1000-6702.2013.01.026.

55. 吴翔,李涛,李学松*.肾脏平滑肌瘤5例分析并文献回顾[J].现代泌尿外科杂志,2013,18(4):398-400. DOI:10.3969/j.issn.1009-8291.2013.04.033.

56. 杨飞亚,姚林,李学松*, 等.腹腔镜双侧腹股沟淋巴结清扫术一例并文献复习[J].中华临床医师杂志(电子版),2013,(6):2696-2698.

57. 邵光军,蔡林,李学松*, 等.脐尿管癌:单中心30年经验总结[J].北京大学学报(医学版),2013,45(5):774-778.

58. 唐琦,杨恺惟,郝翰,李学松*,周利群*.腹腔镜治疗双肾被膜下积液致Page肾一例及文献回顾[J].中华临床医师杂志(电子版),2013,(3):1278-1280.

59. 方冬#,杨恺惟#, 李学松*，等.腹腔镜治疗大体积肾癌的临床经验及与开放手术的比较[J].现代泌尿外科杂志,2013,18(6):553-556.

60. 方冬,李学松*,谌诚, 等.经腹腔与腹膜后腹腔镜肾癌根治术疗效比较[J].现代泌尿外科杂志,2013,18(2):126-129..

61. 杨恺惟#,方冬#,李学松*, 等.腹腔镜下不同手术入路治疗大体积肾癌的效果比较[J].中华临床医师杂志(电子版),2013,(21):9458-9461.

62. 王天昱,陈晓鹏,李学松*, 等.前列腺癌近距离治疗的效果和不良反应分析[J].现代泌尿外科杂志,2013,18(4):322-328.

63. 吴翔,李涛,高祥勋,李学松*.肾脏肿瘤穿刺活检病理分型与组织学分级诊断准确性分析[J].中华临床医师杂志(电子版),2012,06(15):4185-4189.

64. 李子然,李学松*.对于包皮环切术的争议[J].中华临床医师杂志(电子版),2012,6(18):140-143.

65. 张中元,李学松*,周利群*.肾脏肿瘤评分系统的研究新进展[J].微创泌尿外科杂志,2012,1(1):20-23.

66. 申海涛,郝瀚,连庆文,李学松*,周利群.后腹腔镜下离断式肾盂成形术48例治疗体会[J].中华临床医师杂志(电子版),2012,06(15):4454-4455.

67. 吴翔,李学松*,何志嵩*,周利群.舒尼替尼治疗转移性肾癌的进展[J].中华临床医师杂志(电子版),2012,6(3):655-658.

68. 张中元,唐琦,李学松*, 等.R.E.N.A.L.肾肿瘤评分系统用于保留肾单位手术的临床分析[J].北京大学学报(医学版),2012,44(4):539-543.

69. 郑卫,吴鑫,张雷,宋刚,张争,龚侃,宋毅,李学松*,何志嵩*,周利群.腹腔镜膀胱全切手术:单中心60例学习曲线结果分析[J].北京大学学报(医学版),2012,44(4):558-562.

70. 胡佩胜,何睿,杨新宇,李学松*,周刊群,何志嵩,郭应禄.腹腔镜治疗精囊囊性神经鞘瘤一例并文献回顾[J].中华临床医师杂志(电子版),2012,6(3):714-715.

71. 毕金文,周亮亮,李学松*, 等.后肾腺瘤的临床及病理分析并文献复习[J].中华临床医师杂志(电子版),2011,05(3):868-870.

72. 王天昱,陈晓鹏,李学松*, 等.前列腺特异性抗原和Gleason评分对前列腺癌患者核素骨扫描结果的预测价值[J].北京大学学报(医学版),2012,44(4):528-534.

73. 陈晓鹏,汤坚强,李学松*, 等.回肠代输尿管术治疗长段输尿管缺损一例报道并文献复习[J].中华临床医师杂志(电子版),2011,05(8):2410-2413.

74. 刘荣耀,赵鹏举,李学松*, 等.经腹腔完全腹腔镜肾输尿管全长切除术治疗上尿路尿路上皮癌[J].北京大学学报(医学版),2011,43(4):531-534.

75. 谌诚,周亮亮,李学松*, 等.嗜铬细胞瘤诊疗:单中心142例报告[J].中华泌尿外科杂志,2011,32(1):35-37.

76. 吴翔,于楠,高莹,李学松*, 等.舒尼替尼致转移性肾细胞癌患者甲状腺功能异常的临床分析[J].中华临床医师杂志(电子版),2011,05(3):659-662. DOI:10.3877/cma.j.issn.1674-0785.2011.03.005.

77. 张崔建,杨新宇,李学松*, 等.肾脏非成熟囊性畸胎瘤一例报道及文献回顾[J].中华临床医师杂志(电子版),2010,04(12):2563-2566. DOI:10.3877/cma.j.issn.1674-0785.2010.12.042.

78. 荣建红,张岩,李学松*, 等.泌尿系子宫内膜异位症的诊断及治疗(附22例报告)[J].北京大学学报(医学版),2010,42(4):461-464. DOI:10.3969/j.issn.1671-167X.2010.04.023.

79. 李学松#,宋毅,龚侃, 等.舒尼替尼治疗转移性肾脏透明细胞癌的临床研究[J].中华外科杂志,2010,48(5):375-377. DOI:10.3760/cma.j.issn.0529-5815.2010.05.015.

80. 李学松#,龚侃,孙国锋, 等.Bcl-2和Bax在前列腺癌不同周期时相的表达[J].中华外科杂志,2008,46(10):768-771. DOI:10.3321/j.issn:0529-5815.2008.10.013.

81. 李日清,李学松*,张祥华, 等.原发性附睾肿瘤——附42例报告[J].中华临床医师杂志(电子版),2007,1(7):14-17. DOI:10.3969/j.issn.1674-0785.2007.07.006.

82. 李学松#,李淑清,何志嵩, 等.射频消融治疗肾肿瘤[J].中华临床医师杂志(电子版),2007,1(7):7-10. DOI:10.3969/j.issn.1674-0785.2007.07.003.

83. 李学松#,李日清,张祥华, 等.腹腔镜在苗勒管持续存在综合征诊断治疗中的应用——病例报告附录像[J].中华临床医师杂志(电子版),2007,1(7):50-51. DOI:10.3969/j.issn.1674-0785.2007.07.017.

84. 李学松#,周利群,何志嵩, 等.聚集素在前列腺癌细胞不同周期时相的表达[J].中华泌尿外科杂志,2006,27(1):36-39.

85. 李学松#,厉将斌,梁云燕, 等.紫龙金联合雌二醇氮芥对小鼠前列腺癌体内抑瘤作用的研究[J].中华泌尿外科杂志,2005,26(12):803-805.

86. 李学松#,肖云翔,周利群, 等.成人前列腺囊高分化鳞癌一例[J].中华外科杂志,2005,43(2):135.

87. 李学松#,白龙伟,陈捷, 等.肾脏平滑肌瘤三例报告[J].中华泌尿外科杂志,2004,25(10):675.

88. 李学松#,梁云燕,王代树, 等.紫龙金对前列腺癌细胞系DU-145的体外作用[J].中华实验外科杂志,2004,21(6):720-722.

89. 李学松#,梁云燕,王代树, 等.复方中药紫龙金对前列腺癌的体外作用[J].中华泌尿外科杂志,2004,25(8):516-520.

90. 李学松#,梁云燕,王代树, 等.复方中药紫龙金对前列腺癌细胞系LNCaP的体外作用[J].中国中西医结合杂志,2004,24(7):621-624.

91. 李学松#,何志嵩*.激素难治性前列腺癌治疗进展[J].中国肿瘤,2003,12(12):699-703. [1]

2014，2015，2016年度中国医师百强榜膀胱癌专业上榜专家

2015年获得第一届郭应禄泌尿外科青年医师奖

2017年获得华夏医学科技奖二等奖、中华医学科技奖叁等奖

2018年获得教育部高等学校科学研究优秀成果奖(教育部奖)二等奖

2018年北京市科技进步叁等奖

2018年转化实用新型专利1项

2019年获得世界华人泌尿外科学会新星奖

2019年获得国之名医 优秀风范奖

2020年获得北京医学会首都青年医学创新与转化大赛一等奖